This is a correction to the Research and Development Update announcement published at 7:00am on 24 February 2021 (RNS number 1141Q) which has been amended with the following underlined additions to make it consistent with the French announcement released on Euronext at 8am CET on 24 February 2021. http://novacyt.com/wp-content/uploads/2021/02/Novacyt-RD-Update-24.02.2021-correction-ENGLISH.pdf
Visit PageYear: 2021
Point sur la Recherche & Développement
Paris, France et Camberley, Royaume-Uni – 24 février 2021 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, fait le point sur l’avancement de ses programmes de recherche et développement (R&D) en cours, y compris le développement de son portefeuille de produits, les essais cliniques et la publication des validations
Visit PageResearch and Development Update
Paris, France and Camberley, UK – 24 February 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the progress of its near-term research and development programmes, including the expansion of its product portfolio, clinical trial activity and the publication of independent validations of the Company’s COVID-19
Visit Page